The Journal of Rheumatology最新文献_第5页

Acrocyanosis After Immunotherapy: Vasculitis or Vasculopathy? New Iatrogenic Disease Case Series From CanRIO. 免疫治疗后Acrocyanosis：血管炎还是血管病变？来自CanRIO的新医源性疾病病例系列。

The Journal of Rheumatology Pub Date : 2025-04-15 DOI: 10.3899/jrheum.2024-0486

Yuliya Lytvyn,Megan E Himmel,Carrie Ye,Shahin Jamal,Alexandra P Saltman,

引用次数: 0

Frailty and Associated Outcomes in Patients with Vasculitis. 血管炎患者的虚弱和相关结局。

The Journal of Rheumatology Pub Date : 2025-04-15 DOI: 10.3899/jrheum.2024-1079

Sebastian E Sattui,John Stadler,Renee L Borchin,Cristina Burroughs,Laura Gandolfo,David Cuthbertson,Christine Yeung,Kalen Larson,Peter A Merkel,Robert Spiera,

{"title":"Frailty and Associated Outcomes in Patients with Vasculitis.","authors":"Sebastian E Sattui,John Stadler,Renee L Borchin,Cristina Burroughs,Laura Gandolfo,David Cuthbertson,Christine Yeung,Kalen Larson,Peter A Merkel,Robert Spiera,","doi":"10.3899/jrheum.2024-1079","DOIUrl":"https://doi.org/10.3899/jrheum.2024-1079","url":null,"abstract":"OBJECTIVETo describe the frequency and outcomes associated with self-reported frailty in patients with vasculitis.METHODSVascStrong is a longitudinal study utilizing the Vasculitis Patient-Powered Research Network, an internet-based cohort of patients with vasculitis. Data collected included patient global assessment (PGA) and several domains of the Patient-Reported Outcomes Measurement Information Systems (PROMIS). Frailty was measured at baseline and 1-year follow-up using the FRAIL scale, a 5 domain self-reported measure. Patients were classified as non-frail, pre-frail, and frail based on 0, 1-2, or ≥3 criteria, respectively. At follow-up, patients reported the occurrence over the prior year of hospitalizations, infections, fractures, and disease flares. A multivariable logistic regression was performed to identify factors associated with frailty.RESULTSThe baseline survey included 328 patients. Patients had a mean age of 59.5 years, were predominantly female (71.6%) and non-Hispanic white. Prevalence of pre-frailty and frailty was 42.1% and 21.6%, respectively. The majority of patients with each form of vasculitis were classified as frail or pre-frail. Pre-frail and frail patients reported worse PROMIS scores at baseline and follow-up. Frailty was independently associated with female sex, higher PGA scores, being overweight, and obesity, but not with age. At 1-year, 272/328 (82.9%) patients answered the follow-up survey. Transitions in frailty status were observed in 99 (36.4%) patients. Hospitalizations and flares were more frequent in frail patients.CONCLUSIONSelf-reported frailty or pre-frailty is common in the majority of patients with multiple forms of vasculitis, indicating there is a substantial subset of patients at risk for worse outcomes.","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"29 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143841194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Survival After Lung Transplantation in Patients With Rheumatoid Arthritis-Associated Lung Disease. 类风湿关节炎相关肺部疾病患者肺移植后的生存率

The Journal of Rheumatology Pub Date : 2025-04-15 DOI: 10.3899/jrheum.2025-0025

Amir A Razmjou,Angela Pham,Elizabeth R Volkmann,Veena K Ranganath

引用次数: 0

Effective treatment of Jak1/3 inhibitor in Blau syndrome from a multi-center retrospective study in central China. Jak1/3抑制剂对Blau综合征的有效治疗——华中地区一项多中心回顾性研究

The Journal of Rheumatology Pub Date : 2025-04-15 DOI: 10.3899/jrheum.2024-0822

Yangyang Hu,Pengcheng Li,Jinhua Liu,Zhipeng Zeng,Xiong Zhang,Wen Yin,Hai Xu,Jing Cai,Yikai Yu

{"title":"Effective treatment of Jak1/3 inhibitor in Blau syndrome from a multi-center retrospective study in central China.","authors":"Yangyang Hu,Pengcheng Li,Jinhua Liu,Zhipeng Zeng,Xiong Zhang,Wen Yin,Hai Xu,Jing Cai,Yikai Yu","doi":"10.3899/jrheum.2024-0822","DOIUrl":"https://doi.org/10.3899/jrheum.2024-0822","url":null,"abstract":"OBJECTIVETo investigate the effectiveness of the JAK 1/3 inhibitor tofacitinib in treating Blau syndrome and explore the association between various clinical and genetic features and therapeutic responses within the cohort.METHODSA five-year, multi-center, retrospective, observational study was conducted across seven centers, focusing on genetic profiles and the clinical manifestations of cohort. Genetic analysis, including whole exome sequencing and NOD-2 and STAT3 rs2293152 phenotypic comparisons, was performed to assess therapeutic responses.RESULTSBaseline data for the cohort, with a median disease duration of 9.3 years. All patients exhibited arthritis, with 2 cases being oligoarticular and 22 polyarticular. The median joint count involved was 6, primarily affecting wrists, proximal interphalangeal joints, ankles, and knees. Radiographic analysis revealed symmetrical non-erosive arthropathy in 92.3% of patients. Notably, two-thirds of the cohort displayed previously unrecognized dysplastic bone changes. Ocular involvement was observed in all patients. Notably, no association was found between different NOD-2 sequences and therapy response. Conversely, patients harboring the STAT3 rs2293152 GG polymorphism demonstrated favorable responses treatment, regardless of whether JAK1/3 inhibitors or TNF-α inhibitors were used.CONCLUSIONTofacitinib could be an effective therapeutic option for BS patients who demonstrate resistance to TNF-α inhibitors or corticosteroids. Specifically, the STAT3 rs2293152 GG polymorphism was associated with improved response to treatment, suggesting a genotype-influenced therapeutic efficacy.","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"3 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143841193","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Patients' perspectives and experiences with medication for gout: A thematic synthesis of qualitative studies. 痛风患者用药的观点和经验：定性研究的专题综合。

The Journal of Rheumatology Pub Date : 2025-04-15 DOI: 10.3899/jrheum.2024-1021

Olav Tvedten,Sacha Bossina,Muguet Koobasi,Allison Jaure,Brian Liang,Clarice Tang,Kathleen Tymms,Gabor Major,Ayano Kelly

引用次数: 0

Canadian Rheumatology Association Guidance for Developing & Endorsing Quality Measures to Support Learning Health Systems. 加拿大风湿病协会制定和认可质量措施以支持学习卫生系统的指南。

The Journal of Rheumatology Pub Date : 2025-04-15 DOI: 10.3899/jrheum.2024-1065

Racheal Githumbi,Claire E H Barber,Susan J Bartlett,Karine Toupin-April,Marinka Twilt,Diane Lacaille,Cheryl Barnabe,Kiran Dhiman,Alison M Hoens,Adrian Grebowicz,Tara McMillan,Jessica Widdifield

{"title":"Canadian Rheumatology Association Guidance for Developing & Endorsing Quality Measures to Support Learning Health Systems.","authors":"Racheal Githumbi,Claire E H Barber,Susan J Bartlett,Karine Toupin-April,Marinka Twilt,Diane Lacaille,Cheryl Barnabe,Kiran Dhiman,Alison M Hoens,Adrian Grebowicz,Tara McMillan,Jessica Widdifield","doi":"10.3899/jrheum.2024-1065","DOIUrl":"https://doi.org/10.3899/jrheum.2024-1065","url":null,"abstract":"OBJECTIVETo review methods for developing and endorsing Quality Measures (QMs) to inform a national quality measurement framework for rheumatology care in Canada.METHODSWe conducted a rapid environmental scan of measure development organizations from Canada, the United Kingdom, the United States and Australia. Major phases in the development of QMs were abstracted. The results were reviewed and synthesized with members of the Canadian Rheumatology Association's Digital Measurement Subcommittee through iterative review across 3 virtual meetings. The guidance was approved at the committee and the CRA board level.RESULTSFive key steps in the measure development cycle are proposed including: conceptualization and prioritization, measure specification development, testing and validation, implementation and reporting, continuous evaluation and maintenance. Foundational to all phases is the engagement of individuals from diverse backgrounds with lived experience of disease, healthcare providers, quality measurement scientists, and partner organizations. Measures should be aligned with domains of quality (effectiveness, efficiency, equity, patient-centeredness, safety and timeliness of care delivery) and be developed transparently. Endorsement of future QMs should, at minimum, prioritize validity, feasibility and acceptability or use/usability.CONCLUSIONThis paper establishes a comprehensive and relevant framework for the development and/or endorsement of QMs in Canadian rheumatology care. This framework will permit streamlining of future quality improvement efforts at the national level.","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"4 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143841203","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Update to a Systematic Review on Quality Measures for Rheumatoid Arthritis. 类风湿关节炎质量评价系统综述的最新进展。

The Journal of Rheumatology Pub Date : 2025-04-15 DOI: 10.3899/jrheum.2024-1314

Racheal Githumbi,Steven J Katz,Jessica Widdifield,Claire E H Barber

{"title":"Update to a Systematic Review on Quality Measures for Rheumatoid Arthritis.","authors":"Racheal Githumbi,Steven J Katz,Jessica Widdifield,Claire E H Barber","doi":"10.3899/jrheum.2024-1314","DOIUrl":"https://doi.org/10.3899/jrheum.2024-1314","url":null,"abstract":"OBJECTIVEThis work aims to provide an update on a previously published systematic review on quality measures (QMs) in rheumatoid arthritis (RA) to inform future measure development and endorsement efforts.METHODSWe searched published and grey literature sources from January 2018-July 2023. Included sources were limited to those that targeted RA patients, either exclusively or alongside other rheumatic conditions and were guided by a clear consensus-building methodology. We extracted QMs and categorized them into topic and subtopics. Extracted measures were then reviewed for similarity with the previously extracted set from a published systematic review. Non-duplicative measures were labelled as \"new\".RESULTSThe updated search resulted in 2395 citations from which 339 studies were selected for full text review. From these, a total of six studies met the inclusion/exclusion criteria resulting in the extraction of 156 QMs, along with 31 additional QMs extracted from 87 grey literature sources. Amongst the 187 extracted QMs, most were duplicative and/or similar to previously developed measures (68%, n= 127). 60 were identified as \"new\". New QMs were primarily structural (50%, n= 30) and process measures (33%, n= 20). New QMs frequently addressed the topic of health care delivery (35%, n= 21).CONCLUSIONWhile this review identified new QMs that reflect various reassuring trends in healthcare quality assessment, most were duplicative/similar to existing measures. This highlights the need for a centralized way to reduce redundancy in QM development efforts, and enable easy dissemination of QMs to optimize care for individuals with RA.","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"218 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143841018","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

How Should We Count the Toe Joints in the 66/68 Joint Count in Psoriatic Arthritis? Results of an International Survey. 银屑病关节炎66/68关节计数中如何计算脚趾关节？一项国际调查结果。

The Journal of Rheumatology Pub Date : 2025-04-15 DOI: 10.3899/jrheum.2025-0072

Gabriele De Marco,Helena Marzo-Ortega,Philip S Helliwell

引用次数: 0

Outcomes in Systemic Sclerosis-Associated Interstitial Lung Disease Based on Serological Profiles: Focus on Anti-Centromere and Anti-RNA Polymerase III Antibodies. 基于血清学特征的系统性硬化症相关间质性肺疾病的预后：关注抗着丝粒和抗rna聚合酶III抗体

The Journal of Rheumatology Pub Date : 2025-04-15 DOI: 10.3899/jrheum.2024-1063

Elizabeth R Volkmann,Shervin Assassi,Christopher P Denton,Rozeta Simonovska,Steven Sambevski,Margarida Alves,Elana J Bernstein

{"title":"Outcomes in Systemic Sclerosis-Associated Interstitial Lung Disease Based on Serological Profiles: Focus on Anti-Centromere and Anti-RNA Polymerase III Antibodies.","authors":"Elizabeth R Volkmann,Shervin Assassi,Christopher P Denton,Rozeta Simonovska,Steven Sambevski,Margarida Alves,Elana J Bernstein","doi":"10.3899/jrheum.2024-1063","DOIUrl":"https://doi.org/10.3899/jrheum.2024-1063","url":null,"abstract":"OBJECTIVECompare the progression of systemic sclerosis-associated interstitial lung disease (SSc-ILD) based on serological status.METHODSIn a post-hoc analysis of the SENSCIS trial (nintedanib vs placebo in SSc-ILD; NCT02597933), we analyzed the rate of decline in forced vital capacity (FVC) over 52 weeks in 3 subsets: positive for anti-centromere antibody (ACA), positive for anti-RNA polymerase III antibody (ARA), negative for ACA, ARA and anti-topoisomerase I antibody (ATA).RESULTSAmong study participants who underwent baseline serological evaluation, 32/549 (5.8%) were ACA positive, 98/528 (18.6%) were ARA positive, and 127/526 (24.1%) were negative for ACA, ARA and ATA. Among the serological subsets of interest, in the placebo arm, the adjusted rate (SE) of decline in FVC (mL/year) was -31.2 (41.5) among participants who were positive for ACA and -64.7 (35.1) among participants who were positive for ARA, numerically lower than in the overall SENSCIS trial population (-93.3 [13.5]). However, participants who were negative for ACA, ARA and ATA experienced a numerically greater rate of decline in FVC (mL/year) than the overall trial population, both in those randomized to placebo (-115.6 [35.4] vs. -93.3 [13.5], respectively) and those randomized to nintedanib (-91.8 [34.3] vs. -52.4 [13.8]).CONCLUSIONThese analyses of data from the SENSCIS trial suggest that patients with SSc-ILD who are ACA positive or ARA positive can experience progression of SSc-ILD. Patients negative for ACA, ARA and ATA had a higher rate of progression than the overall trial population and should be monitored closely.","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"74 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143841197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Increased school absence among children with juvenile idiopathic arthritis - a national matched comparison study. 青少年特发性关节炎儿童缺课率增加——一项全国性匹配比较研究。

The Journal of Rheumatology Pub Date : 2025-04-15 DOI: 10.3899/jrheum.2024-1182

Malthe Jessen Pedersen,Christian Høst,Stefan Nygaard Hansen,Jens Klotsche,Kirsten Minden,Bent Deleuran,Bodil Hammer Bech

{"title":"Increased school absence among children with juvenile idiopathic arthritis - a national matched comparison study.","authors":"Malthe Jessen Pedersen,Christian Høst,Stefan Nygaard Hansen,Jens Klotsche,Kirsten Minden,Bent Deleuran,Bodil Hammer Bech","doi":"10.3899/jrheum.2024-1182","DOIUrl":"https://doi.org/10.3899/jrheum.2024-1182","url":null,"abstract":"OBJECTIVEThis study compares rates of school absence (SA) of all children with juvenile idiopathic arthritis (JIA) attending public Danish schools to peers both before and after JIA diagnosis. Further, we aimed to investigate the role of socioeconomic status (SES) on the possible association.METHODSWe performed a register-based matched cohort study. We included all children attending public Danish schools between 2010 and 2019 diagnosed with JIA and compared them to school mates. Rates of differentiated and total SA both before and after JIA diagnosis were compared. In the primary study we included children diagnosed with JIA after starting school, whereas the secondary study only included children diagnosed before starting school.RESULTSWe included 716 children with JIA and 3632 matched controls in the primary study and 382 children with JIA and 1910 matched controls in the secondary. Our primary study showed higher rates of sickness SA and total SA from three years before diagnosis and the following five years among children with JIA. After diagnosis, JIA children also had significantly more legal (planned) SA. Children diagnosed with JIA before starting school (secondary study) had significantly more SA (both sickness SA and legal school SA) up to 8th grade. In both studies children of low SES both with and without JIA had highest rates of SA, although no difference in the association between JIA and SA across SES groups were found.CONCLUSIONChildren with JIA had more sickness and legal absence from school.","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"50 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143841201","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0